Business Overview: Mirion Technologies, Inc. (NYSE: MIR)

---

Executive Summary

Mirion Technologies, Inc. designs, manufactures, and services radiation detection, measurement, analysis, and monitoring products for the nuclear power, medical, research, and defense industries. The company has grown largely through acquisition — completing 18 deals since 2016 — building a broad portfolio spanning reactor instrumentation, radiation safety equipment, and medical dosimetry and radiation-therapy quality assurance.

Mirion matters because it sits at the center of two structurally growing end markets: a global nuclear power renaissance (new reactor builds and life-extension refurbishments) and the ongoing need for radiation safety and oncology quality-assurance equipment in healthcare, giving it exposure to both a cyclical capex upswing and a sticky, recurring services base.

---

1. Core Business Model & How They Work

Mirion sells detection and monitoring instruments directly and through independent sales representatives and distributors, then captures recurring revenue from the replacement, calibration, and servicing of its large installed base.

[ Instrument/System Sale to Nuclear/Medical Customer ] ➡️ [ Long-Cycle Installation (12-36 months for new-build) ] ➡️ [ Installed Base Requires Recalibration/Replacement ] ➡️ [ Recurring Service & Dosimetry Revenue ]

Key Operational Drivers

1. Recurring revenue from the installed base: Over 80% of Nuclear & Safety end-market revenue comes from replacement, upgrade, service, and recalibration cycles tied to equipment already in the field, giving Mirion a highly visible, repeatable revenue stream.
2. Long-cycle contracts and backlog: Nuclear new-build and refurbishment sales cycles run 12 to 36 months, and remaining performance obligations reached $1,104.3 million at year-end 2025 (up from $811.9 million), with about 49% expected to convert to revenue in 2026 — a strong forward indicator of demand.
3. Acquisition-led capability expansion: Recent deals — Certrec (July 2025, nuclear regulatory compliance software) and Paragon Energy Solutions (December 2025, nuclear power products/services) — extend Mirion deeper into adjacent, higher-margin software and services tied to its core detection hardware.
4. Seasonality tied to outage schedules: Sales and cash flow peak in Q4, driven by customer capital spending and fall nuclear plant outages, when reactors are taken offline for maintenance and instrumentation work.

---

2. Business Segments

┌──────────────────────────────────────┐
│          Mirion Technologies            │
└───────────────────┬────────────────────┘
                     │
        ┌────────────┴─────────────┐
        ▼                           ▼
┌─────────────────────┐    ┌─────────────────────┐
│  Nuclear & Safety     │    │      Medical          │
│  (nuclear power,      │    │  (cancer care QA,     │
│   labs/research,      │    │   nuclear medicine,   │
│   defense/industrial)  │    │   occupational        │
│                        │    │   dosimetry)          │
└─────────────────────┘    └─────────────────────┘

Nuclear & Safety (formerly "Technologies")

Radiation monitoring systems, reactor instrumentation and control detectors, waste management systems, laboratory spectroscopy and counting systems, and military CBRNE detection — serving nuclear power plants, research labs, and defense/industrial customers.

Medical

Cancer care (radiation therapy quality assurance via the SunCHECK platform and AI-based oncology software Oncospace), nuclear medicine dose calibrators and hot-lab solutions, and occupational dosimetry services providing dose-of-record reporting via Instadose.

---

3. Product Portfolio

---

4. Competitive Landscape

• Nuclear & Safety competitors: Thermo Fisher Scientific, Curtiss-Wright, Ortec (Ametek), FLIR (Teledyne), Ludlum, Fuji Electric, Caen System, Fluke (Fortive), Berthold Technologies, and Framatome — a mix of large diversified conglomerates and specialized radiation-detection firms.
• Medical competitors: Landauer (Fortive), PTW, IBA, Standard Imaging, Comecer, and LAP — specialized radiation therapy QA and dosimetry providers.
• Mirion competes on product quality and reliability, technical capability and qualification, customer relationships, service, and price, with brand recognition mattering especially in medical dosimetry purchasing decisions.

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Deep regulatory qualification requirements in both nuclear instrumentation and medical radiation safety create high barriers to entry — new detection equipment must pass extensive nuclear-industry and FDA-adjacent certification before it can be installed.
• Large, growing backlog ($1.1 billion in remaining performance obligations, up 36% year-over-year) signals durable demand from the global nuclear renaissance and reactor life-extension programs.
• High recurring-revenue mix (80%+ of Nuclear & Safety revenue from service/replacement cycles) smooths what would otherwise be a lumpy, capital-equipment-driven business.
• Breadth across nuclear, medical, research, and defense diversifies Mirion's exposure across multiple government and commercial end markets with different funding cycles.

Risks

• History of net losses: Mirion posted net losses of $(98.7) million in 2023 and $(36.6) million in 2024 before turning a modest $29.8 million profit in 2025, with an accumulated deficit of $512.7 million — the path to sustained profitability is still recent and unproven over a long cycle.
• Long sales and installation cycles (12-36 months for nuclear new-build) expose Mirion to project delays, cost overruns, and the risk that customer capital spending plans shift or slip.
• Heavy reliance on continued global nuclear power investment: a slowdown in new reactor construction or refurbishment spending (whether from policy shifts, financing constraints, or public sentiment) would directly pressure the largest segment.
• Integration risk from its acquisition-heavy growth model — 18 deals since 2016 means a meaningful share of Mirion's capabilities (and goodwill) come from businesses that must be successfully integrated and cross-sold.

---

6. Financial Overview

---

7. Summary Conclusion

Mirion Technologies occupies a genuinely favorable structural position: it sells mission-critical, heavily regulated radiation detection and monitoring equipment into a nuclear power industry experiencing a global resurgence, while its medical dosimetry and radiation-therapy QA businesses provide a steadier, less cyclical counterweight. Its large and growing backlog, combined with a high recurring-revenue mix on its installed base, gives real visibility into future results.

The company's biggest forward question is whether its recent return to profitability (after two consecutive years of net losses) is durable, and whether it can keep successfully integrating an acquisition-heavy growth strategy while the global nuclear buildout — the single biggest driver of its backlog — continues to materialize on the long, multi-year timelines the industry requires.